Published online March 1, 2007
PEDIATRICS Vol. 119 Supplement March 2007, pp. S125-S130 (doi:10.1542/peds.2006-2023C)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Klein, G. L. Articles by Holm, I. A. Search for Related Content PubMed PubMed Citation Articles by Klein, G. L. Articles by Holm, I. A. Related Collections Therapeutics & Toxicology Social Bookmarking                         What's this?

SUPPLEMENT ARTICLE

Effects of Pharmacologic Agents on Bone in Childhood: An Editorial Overview

Gordon L. Klein, MD, MPH^a, Laura K. Bachrach, MD^b and Ingrid A. Holm, MD, MPH^c

^a Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas
^b Department of Pediatrics, Stanford University School of Medicine, Stanford, California
^c Division of Endocrinology, Children's Hospital of Boston, Boston, Massachusetts

Key Words: anabolic steroids • glucocorticoids • bisphosphonate • areal bone mineral density • antiepileptic drugs

Abbreviations: ASBMR, American Society for Bone and Mineral Research • BMD, bone mineral density • VDR, vitamin D receptor • DXA, dual-energy x-ray absorptiometry • QCT, quantitative computed tomography • OI, osteogenesis imperfecta • rhGH, recombinant human growth hormone

The first 300 words of the full text of this article appear below.

On April 14, 2005, a workshop on the skeletal effects of pharmacologic agents in children was held at the National Institutes of Health. Jointly sponsored by the American Society for Bone and Mineral Research (ASBMR) and the National Institute of Child Health and Human Development, the meeting was organized in response to suggestions from the Pediatric Bone Initiative of the ASBMR.¹ Previous discussions at the 2003 ASBMR symposium on the state of pediatric bone research¹ led to the conclusion that there was a lack of information on the effects of Food and Drug Administration–approved therapeutic agents on bone in children. Advances in pediatric medicine have produced a new population of children who are able to live into adulthood with chronic illnesses and were previously thought to have a poor prognosis for survival beyond their childhood years. Medications and direct effects of illness may compromise normal bone mineralization, leading to skeletal deformities and osteopenia at a relatively young age. Several topics discussed at the 2003 ASBMR symposium were further examined and developed in the recent National Institutes of Health workshop, such as the limitations of currently available pediatric bone density–reference data, the challenges of measuring bone mass and strength in children, clinical-trial design, chronic drug effects on growing bone, and therapeutic agents for pediatric bone disorders. The following is a summary of all the presentations from the National Institutes of Health workshop on pediatric bone. Detailed summaries of selected talks are provided as well.

The first session provided basic background on normal bone accrual in children, the regulation of skeletal growth, and the effects of calcium, phosphorus, and vitamin D on growing bone.

Dr Jeffrey Baron and his co-workers^2,3 reviewed the role of the growth plate in linear skeletal growth and work from his own laboratory to elucidate mechanisms of growth . . . [Full Text of this Article]

Address correspondence to Gordon L. Klein, MD, MPH, University of Texas Medical Branch, Department of Pediatrics, 301 University Blvd, Galveston, TX 77555-0352. E-mail: gklein@utmb.edu

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?